Objective. Based on several previous clinical studies, we hypothesized that ornithine levels are different among subjects with persistent musculoskeletal pain compared with other subjects in the population.
Introduction
Recent preliminary findings emerging from the modern technology of metabolomics have suggested an association between specific pain conditions and several metabolites, including some well-known amino acids such as glutamate, arginine, tryptophan, ornithine, glycine, and histidine [1, 2] . Of the amino acids, circulating levels of ornithine have been found to be higher in complex regional pain syndrome [1] and rheumatoid arthritis [2] . Furthermore, sleep problems and stress are often associated with long-lasting pain, and ornithine has been suggested to play a role in these disturbances [3] .
Arginine, citrulline, and ornithine are key amino acids of the urea cycle [4] . A precursor of ornithine, glutamate is an important amino acid in neural activity and pain signaling [5] . On the other hand, ornithine is a precursor of proline and polyamines, which are important in wound healing [6, 7] . Furthermore, polyamines (putrescine, spermidine, and spermine) are synthetized from ornithine. Polyamines are suggested to be involved in nociception and edema [7, 8] .
To our knowledge, there are no population-based studies about the relationship between pain and ornithine. Based on several previous non-population-based studies, we hypothesized that ornithine levels are different among subjects with persistent pain compared with other subjects in the population. Therefore, we analyzed circulating ornithine levels and levels of closely related amino acids-glutamic acid, arginine, citrulline, proline, and one of the polyamines (spermidine)-in a population sample of subjects with no pain, nonpersistent pain, or persistent pain.
Methods

Design and Subjects
The present study is based on a cross-sectional study of the Lapinlahti cohort (N ¼ 361) in 2010 [9, 10] . All the participants signed an informed consent form. This study was carried out in compliance with the Helsinki Declaration. Ethics permission for the study was granted by the ethics committee of the Kuopio University Hospital (number 129/2009).
In 2005, 480 subjects (63% of the whole study population; 230 men and 250 women) underwent a complete health survey (baseline study) that consisted of a structured questionnaire and a health examination conducted by a trained nurse [9, 10] . A similar survey and health examination was conducted in 2010 [11] . The study participants filled out a structured questionnaire including items regarding sociodemograpic factors and lifestyle. Smoking was graded as never smoker, former smoker, occasional smoker, and regular smoker. A subject was regarded as a smoker if he/she smoked regularly or occasionally. Alcohol use was defined as any weekly use of alcohol during the preceding year. In addition, alcohol use was graded as doses (12 g) per week: none, 1-5 doses, 6-9 doses, at least 10 doses. Physical activity was graded as low (exercise less than once a week), moderate (from one to two times a week), or high (at least three times a week) [10] . Prevalence of chronic diseases was based on self-reports. Use of regular medication and analgesics was based on self-reports. Depressive symptoms were assessed using the 21-item Beck Depression Inventory (BDI-21) with a range of 0 to 63, and a BDI-21 score of 10 or more was used as a cutoff point for clinically important depressive symptoms [12] . The health examination included measurements of weight and height. Body mass index (BMI) was calculated as kg/m 2 .
Definition of Pain
Musculoskeletal pain was defined as pain experienced during the preceding week in any part of the body, reported separately for the neck, shoulders, arms, elbows, forehands, wrists, hands, back, trunk, buttocks, hips, thighs, knees, legs, ankles, or feet. Duration of pain was asked, and pain lasting for more than three months was regarded as chronic. Frequency of pain was asked, and pain occurring every day or continuously was regarded as daily pain [9] . To define persistent pain, three categories of pain status were formed: 1) no pain, 2) nondaily or nonchronic pain (nonpersistent pain), and 3) daily chronic pain (persistent pain).
Laboratory Analysis
All the basic laboratory investigations were performed according to the protocol of the Kuopio University Hospital's accredited medical laboratory, and the values are based on fasting fresh samples of whole blood or plasma in 2010 [11] . Glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [13] .
For the amino acid (glutamic acid, ornithine, citrulline, arginine, proline, and spermidine) analysis, serum samples were collected from all the participants and stored at À70 C until further analysis. Briefly, 10 mL of labeled internal standard mixture was added to 100 mL of serum samples and metabolites were extracted by adding four parts (1:4, sample: extraction solvent) of a 100% acetonitrile þ 1% formic acid solvent. Extracts were vacuum filtered (Hamilton, Reno, NV, USA; delta pressure 300-400 mbar for 2.5 minutes) and injected into the LC system. Metabolites were separated using Acquity UPLC and analyzed using XEVO TQ-S Triple Quadrupole LC/ MS (Waters Corporation, Milford, MA, USA). A detailed description of instrument parameters is given elsewhere [14] .
Statistical Analysis
The results are presented using means, standard deviation, and frequency distributions. Statistical comparisons were made by using the chi-square test or FisherFreeman test for the categorical variables and analysis of variance (ANOVA) for continuous variables. The P values for pairwise group comparisons were adjusted for multiplicity using Hommel's multiple comparison procedure to identify significant differences in at least one of the two between-group comparisons (P < 0.05). The bootstrap method was used when the theoretical distribution of the test statistics was unknown or in the case of violation of the assumptions (e.g., non-normality). The normality of the variables was tested by using the Shapiro-Wilk W test. Ninety-five percent confidence
intervals (CIs) were obtained by bias-corrected bootstrapping (5,000 replications). All reported P values are two-sided, and statistical significance was set at a value of less than .05. The STATA 14.0 (StataCorp, LP, College Station, TX, USA) statistical package was used for the analyses.
Results
Characteristics of the Participants
Subjects with persistent pain were slightly older and less educated than the other subjects ( Table 1 ). The proportions of subjects who used alcohol and those who had a high level of physical activity were lower among subjects with persistent pain. The proportion of subjects with clinically important depressive symptoms was bigger among subjects with persistent pain compared with subjects without pain or with nonpersistent pain. Use of antidepressive medication, paracetamol, and opioids was most common in the persistent pain group. There were no significant differences between groups in chronic diseases.
Concentrations of Glutamic Acid, Ornithine, Citrulline, Arginine, Proline, and Spermidine Table 2 displays the crude concentrations of glutamic acid, ornithine, citrulline, arginine, proline, and spermidine in men and women according to pain status. Compared with subjects without pain, ornithine concentrations in general were higher among subjects with pain in men and women. The ornithine concentrations were the highest in those with persistent pain, especially in women. In men, there was a difference between the no pain and nonpersisting pain and between the no pain and persisting pain. In women, there was a difference between the no pain and persisting pain and between nonpersisting pain and persisting pain. There were no significant differences between the pain groups for any of the other investigated amino acids.
The relative adjusted sex-specific concentrations (z-scores) are presented in Figure 1 . Differences in the levels of ornithine were found between the three pain groups (P ¼ 0.025, adjusted for age, sex, smoking, BMI, physical activity, and depressive symptoms). Furthermore, ornithine concentrations were significantly higher in subjects with persistent pain compared with the no pain (adjusted P ¼ 0.006) and nonpersistent pain (adjusted P ¼ 0.032) groups.
Discussion
To our knowledge, this is the first population-based study suggesting that circulating ornithine level is associated with persistent musculoskeletal pain in a general population sample. Glutamic acid, arginine, citrulline, proline, and spermidine levels were not associated with pain. These results are in line with the few previous studies focusing on specific pain conditions [1, 2] .
In general, the relationship between ornithine levels and musculoskeletal pain can be viewed as moderate. However, it was statistically significant and the profile of this relationship was clearly different from other amino acids concerned here, in line with our original hypothesis. Ornithine concentrations were the highest in those with persistent pain, especially in women. Contrary to men, in women the ornithine levels were not significantly elevated in the nonpersisting pain group compared with subjects with no pain. The reason for this finding is unclear. One possible explanation could be that compared with women men do not experience or report musculoskeletal pain as intensive or persistent, and hence in men more serious cases may have been included also in the nonpersistent pain category [15] . In general, women have lower pain thresholds and higher pain ratings and less tolerance to a range of painful stimuli [15, 16] . Hormones can impact nociception in many ways [16] . Therefore another explanation could be that there is a biological sex difference in the metabolism of ornithine related to pain. For example, it has been suggested that estrogen may reduce the musculotendinous protein turnover and stiffness of the tendon [17] . However, the exact role of estrogen in possible pain-related ornithine metabolism remains unclear. Based on these results, it is not justified to state that elevated ornithine levels are a marker of musculoskeletal pain in general. However, it can be hypothesized that higher levels of ornithine can be found in individuals with persistent chronic musculoskeletal pain.
The possible mechanisms behind the relationship between musculoskeletal pain and ornithine are unclear. Glutamate (i.e., an ionized form of glutamic acid) is converted to ornithine [18] . Glutamate is important in neural signaling of pain [5] . There was a trend toward higher glutamic acid levels among subjects with persistent pain, suggesting that elevated ornithine levels may be partly explained by increased glutaminergic activity of the subjects with pain. However, the association between glutamic acid and pain was nonsignificant and weaker than that between pain and ornithine. It has previously been found that glutamic acid may be elevated in depression [19] . In that study, ornithine levels were even lower, although insignificantly so, in patients with depression compared with controls [19] . In our analysis, however, we adjusted the multivariate models for depression. Therefore, it is unlikely that our finding is due to depression among subjects with persistent pain. Higher ornithine levels may be found in elderly subject compared with young ones [20] . Additionally, physical activity can be associated with ornithine levels [21] . In the present analyses, the significantly higher concentrations were found in subjects with persistent pain even after adjusting for age and physical activity.
Ornithine is important in collagen synthesis and wound repair through synthesis of proline [22] . It can be speculated that persistent musculoskeletal pain may represent a condition with a chronic degenerative state with slow tissue damage, similar to osteoarthritis. Thus, elevated levels of ornithine may be part of a compensatory or repair mechanism for tissue damage, which could appear as elevated levels of proline. However, in the present study, proline levels were not associated with pain. It has been hypothesized that endogenously produced polyamines could be involved in inflammatory pain [8] . In the present data, we were able to analyze only one polyamine, spermidine. We detected no differences in spermidine levels between the groups. Recently, circulating ornithine levels have been found to be elevated in subjects with osteoarthritis, which could be due to the overactivity of arginine catabolism [23] . Contrary to that study, we did not find decreased levels of arginine among the subjects with persistent pain. Further, inflammatory signaling may contribute to ornithine metabolism [22] , but in the present study low-grade inflammation estimated with hs-CRP was not associated with pain. 
Persistent pain and stress are closely related [5] . It has been found that ornithine may reduce cortisol levels [3] . One possible explanation for the association between ornithine and pain could be related to stress-induced activation of the HPA axis.
This study was based on a sample of general population adults. It was possible to define pain accurately and form groups according to pain status. However, it is possible that also the nonpersisting pain group included subjects with pain that seriously impacted their life and possible pain-related metabolism. It was possible to control for several potential confounding factors. However, in this kind of population-based study, it was not possible to detect, for example, neuropathic pain among these subjects. The sample was comprised of *Hommel's multiple comparison procedure was used to correct significance levels for post hoc testing (P < 0.05). In men, there was a difference between no pain and nonpersisting pain and between no pain and persisting pain. In women, there was a difference between no pain and persisting pain and between nonpersisting pain and persisting pain.
Sex-specific standardized z-score Figure 1 Sex-specific standardized z-scores of concentrations adjusted for age, glomerular filtration rate, smoking, BMI, physical activity, and depressive symptoms.
individuals from Middle-Eastern Finland, all of whom were of white European descent, and thus these results may not be generalizable to other ethnic groups. Due to the cross-sectional study setting, we were unable to investigate causal relationships between pain and the investigated metabolite levels. Thus, it is possible that pain increases ornithine levels or that elevated ornithine levels are involved in the etiology of chronic pain. These results may suggest a new mechanism related to persistent musculoskeletal pain and even new treatment options. However, further research is needed in order to further study this association between ornithine and pain. The forthcoming studies should address this issue based on a sample that controlled for the potential confounding factors and that consisted of clinically diagnosed subjects having persistent pain assessed with the standardized pain measures and of age-and sexmatched control subjects having no pain. In conclusion, the findings of the present study suggest that elevated ornithine levels are associated with persistent pain in general population adults.
